Moreover, individuals absorb drugs with varying efficiency, depending on the amount of cytochrome P450 3A4
Study 008 is a pharmacokinetic (PK) study being done at Duke University and it is designed to examine the effect of a potent inhibitor of Cytochrome P450 3A4
on FV-100 pharmacokinetics, allowing the Company to better understand potential drug-drug interactions and to further optimize treatment with FV-100.
Changes to the clinical pharmacology section of the label note that trazodone--indicated for the treatment of depression--is a substrate of the cytochrome P450 3A4
(CYP3A4) enzyme and that trazodone metabolism can be inhibited by the CYP3A4 inhibitors ketoconazole, ritonavir, and indinavir.
Cytochrome P450 3A4
(CYP3A4) contributes to the metabolism of a wide variety of drugs and endogenous substrates, such as steroid hormones (1, 2).
The clinical briefing, titled "Human Clinical Trials With AVI-4557 Targeting Cytochrome P450 3A4
," will be presented by Patrick L.
WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; AND CYTOCHROME P450 3A4
The two patents awarded to Astex are European patent EP1 438 337(1) covering the use of the crystal structure of human cytochrome P450 2C9 and GB 2 408 609(2) which covers the use of the crystal structure of human cytochrome P450 3A4
AVI-4557 targets human cytochrome P450 3a4
(P450) and has been used clinically in four drug metabolism trials.
in vivo effect of I'm-Yunity on hepatic cytochrome P450 3A4
John's wort boosts hepatic cytochrome P450 3A4
Abstract #367 Cytochrome P450 3A4
and 1A2 induction in the immortalized hepatocyte line, Fa2N-4, and comparison with primary cultures of human hepatocytes.
The PK study, to be conducted at Duke University in early 2015, is designed to further understand the effect of a potent inhibitor of Cytochrome P450 3A4
on the pharmacokinetics of FV-100, allowing ContraVir to better understand the potential for clinically important drug-drug interactions and to further optimize treatment for Phase 3 development.